Dr. Reddy's Laboratories, Inc.'s Q3 And 9 Months FY15 Financial Results

Dr. Reddy’s Laboratories Ltd. (NYSE: RDY) today announced its unaudited consolidated financial results for the quarter and nine months ended December 31, 2014 under International Financial Reporting Standards (IFRS).

Key Highlights (Q3 FY15)

•Consolidated revenues at Rs. 38.4 billion, year-on-year growth of 9%.

?Revenues from the Global Generics (GG) segment at Rs. 31.7 billion, YoY growth of 8%.

Help employers find you! Check out all the jobs and post your resume.

Back to news